Equities Analysts Set Expectations for EBS Q2 Earnings

Emergent BioSolutions Inc. (NYSE:EBS) – Research analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for shares of Emergent BioSolutions in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter, down from their prior estimate of ($0.18). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.24 EPS and FY2026 earnings at $3.82 EPS.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.22. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $222.20 million during the quarter, compared to the consensus estimate of $218.50 million.

Separately, StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Emergent BioSolutions Stock Up 3.1%

Shares of Emergent BioSolutions stock opened at $6.94 on Monday. Emergent BioSolutions has a one year low of $4.02 and a one year high of $15.10. The company has a market cap of $376.69 million, a P/E ratio of -1.69 and a beta of 2.09. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm has a fifty day moving average of $5.20 and a two-hundred day moving average of $7.75.

Emergent BioSolutions announced that its board has approved a stock repurchase program on Monday, March 31st that allows the company to repurchase $50.00 million in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 19% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the sale, the director now owns 101,100 shares of the company’s stock, valued at approximately $589,413. The trade was a 25.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in shares of Emergent BioSolutions by 361.6% during the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 30,792 shares in the last quarter. New York State Common Retirement Fund boosted its position in Emergent BioSolutions by 41.7% during the fourth quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company’s stock worth $2,928,000 after purchasing an additional 90,113 shares in the last quarter. Invesco Ltd. grew its holdings in Emergent BioSolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock valued at $14,722,000 after purchasing an additional 638,995 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Emergent BioSolutions by 3.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company’s stock valued at $7,328,000 after purchasing an additional 24,985 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Emergent BioSolutions in the fourth quarter valued at $1,831,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.